Mga Batayang Estadistika
| LEI | 54930006QJ0T5AUO1E71 |
| CIK | 730272 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Repligen Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2025 REPLIGEN CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 7, 2025 |
free UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q free UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORAT |
|
| July 29, 2025 |
Repligen Reports Second Quarter 2025 Financial Results Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2025 Financial Results • Revenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growth • Orders grew sequentially and greater than 20% year-over-year • Increasing revenue guidance to range of $715 to $735 million, which represe |
|
| July 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 REPLIGEN CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 15, 2025 |
Certificate of Amendment to the Certificate of Incorporation of Repligen Corporation Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF REPLIGEN CORPORATION Pursuant to Section 242 of the General Corporation Law of the State of Delaware Repligen Corporation, a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: 1. The Certificate of Incorporation of the Corporation, a |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 REPLIGEN CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 REPLIGEN CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 29, 2025 |
Repligen Reports First Quarter 2025 Financial Results Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2025 Financial Results • Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growth • Orders increased sequentially and high-teens year-over-year • Adjusted operating income increased 72% year-over-year • Reiterates 2025 full |
|
| April 29, 2025 |
free UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q free UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORA |
|
| April 4, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definit |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exac |
|
| March 14, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Subsidiary Name Subsidiary Jurisdiction Repligen Sweden AB Sweden Repligen GmbH Germany Repligen Singapore Pte. Ltd. Singapore Repligen Europe B.V. Netherlands Repligen (Shanghai) Biotechnology Co. Ltd. China Repligen Japan LLC Japan Repligen India Private Limited India Repligen Korea Co., Ltd. South Korea ARTeSYN Biosolutions Holdings Ireland Ltd. Irela |
|
| March 3, 2025 |
OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response 2. |
|
| February 20, 2025 |
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2024 Financial Results • Fourth quarter revenue of $168 million and full year revenue of $634 million • Fourth quarter orders and revenues sequentially increased 11% and 8% respectively • Orders outpaced revenue by 6% in the fourth quarter • Provides f |
|
| February 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 REPLIGEN CORPORATION (Exact name of Registrant as Specified in Its Charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 RE |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIG |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 R |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 R |
|
| November 18, 2024 |
free UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q free UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN COR |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 RE |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-146 |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 000-14656 CUSIP Number 759916109 (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K |
|
| November 12, 2024 |
FY2023 Q1 QTD – GAAP to Non-GAAP Reconciliation November 12, 2024 Supplemental Restatement Periods: Q1 2023 to Q2 2024 GAAP to Non-GAAP Reconciliations Exhibit 99. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission |
|
| November 12, 2024 |
Repligen Reports Third Quarter 2024 Financial Results Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2024 Financial Results • Third quarter reported revenue of $155 million, an increase of 10% year-over-year • CDMO revenue and orders both up ~20% year-over-year • Overall order intake outpaced sales by 4% • Full year revenue guidance narrowed to range of $630-$639 mi |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission |
|
| September 18, 2024 |
September 18, 2024 8-K Supplement Exhibit 99.1 Safe Harbor This report contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, statements regarding the expected impact of the Restatement and change in accounting |
|
| August 6, 2024 |
Goodwin Procter LLP 100 Northern Ave., Boston, MA 02110 goodwinlaw.com +1 (617) 570-1000 August 6, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Ms. Mary Mast Ms. Ibolya Ignat Re: Repligen Corporation Form 10-K for the fiscal year ended December 31, 2023 Filed February 22, 2024 File N |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission File |
|
| July 30, 2024 |
Execution Version EXHIBIT 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made as of June 12, 2024 between Repligen Corporation, a Delaware corporation (the “Company”), and Olivier Loeillot (the “Executive”) and shall become effective on September 1, 2024 (the “Effective Date”). This Agreement amends, restates and supersedes in all respects the Employment Agreement between |
|
| July 30, 2024 |
Repligen Reports Second Quarter 2024 Financial Results Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2024 Financial Results • Reports second quarter revenue of $154 million • Second quarter orders of $157 million • Book-to-bill 1.02 for the quarter, 1.01 year-to-date • Achieved first half revenue and order targets • Narrows revenue guidance within previous range fo |
|
| July 30, 2024 |
EXHIBIT 10.1 FOURTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Fourth Amended and Restated Employment Agreement (the “Agreement”) is made this 12th day of June, 2024 between Repligen Corporation, a Delaware corporation (the “Company”), and Anthony Hunt (the “Executive”) and shall become effective on September 1, 2024 (the “Effective Date”). WHEREAS, the Company and the Executive are parties to |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION ( |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 13, 2024 |
EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN ANNOUNCES CEO TRANSITION PLAN Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024 WALTHAM, Mass., June 13, 2024 — Repligen Corporation (NASDAQ:RGEN), a |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| May 1, 2024 |
Repligen Reports First Quarter 2024 Financial Results Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2024 Financial Results • Reports first quarter revenue of $151 million • Increased new modalities revenue by 16% year-over-year • Increased Filtration (non-COVID) revenue by 12% year-over-year • Achieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 1, |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 1, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 19, 2024 |
Repligen Appoints Maggie A. Pax to Board of Directors Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Appoints Maggie A. Pax to Board of Directors WALTHAM, MA – March 19, 2024 – Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen’s board from eight to n |
|
| February 22, 2024 |
Repligen Corporation Compensation Recovery Policy. Exhibit 97.1 REPLIGEN CORPORATION COMPENSATION RECOVERY POLICY Adopted as of October 11, 2023 Repligen Corporation, a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. This Policy supersedes and replaces the Company’s Policy for Recoupment of Incentive Compensation, dated as of September 28, 2019, with respect to Incentive Compensa |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exac |
|
| February 22, 2024 |
EXHIBIT 19.1 REPLIGEN CORPORATION AMENDED AND RESTATED STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND DISCLOSURE & TRADING PROCEDURES FOR INSIDERS December 12, 2023 Repligen Corporation Amended and Restated Statement of Company Policy on Insider Trading and Disclosure & Trading Procedures for Insiders SECTION I This memorandum sets forth the policy of Repligen Corporation (the “Company” or “Re |
|
| February 22, 2024 |
Repligen Corporation Amended and Restated Non-Employee Directors' Compensation Policy. Exhibit 10.5 REPLIGEN CORPORATION AMENDED AND RESTATED NON-EMPLOYEE DIRECTORS’ COMPENSATION POLICY Cash Fees Annual Retainer: Annual Retainer Board of Directors (the “Board”) Each Non-Employee Member of the Board $ 60,000 Additional Retainer for the Chairperson $ 95,000 Audit Committee Committee Chairperson $ 30,000 Other Committee Members $ 10,000 Compensation Committee Committee Chairperson $ 20 |
|
| February 22, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Subsidiary Name Subsidiary Jurisdiction Repligen Sweden AB Sweden Repligen GmbH Germany Repligen Singapore Pte. Ltd. Singapore Repligen Europe B.V. Netherlands Repligen (Shanghai) Biotechnology Co. Ltd. China Repligen Japan LLC Japan Repligen India Private Limited India Repligen Korea Co., Ltd. South Korea ARTeSYN Biosolutions Holdings Ireland Ltd. Irela |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission |
|
| February 21, 2024 |
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2023 Financial Results • Reports fourth quarter revenue of $156 million and full year revenue of $639 million • Continued strength in orders with fourth quarter book-to-bill ratio of 1.03 WALTHAM, Mass., February 21, 2024 — Repligen Corporation (NASDAQ |
|
| February 13, 2024 |
RGEN / Repligen Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Repligen Corp Title of Class of Securities: Common Stock CUSIP Number: 759916109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 6, 2024 |
RGEN / Repligen Corporation / EDDLEMAN ROY T - AMENDMENT NO. 6 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea192701-13ga6royreplien.htm AMENDMENT NO. 6 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 6)* Under the Securities Exchange Act of 1934 Repligen Corporation (Name of Issuer) Common Stock, $.01 par value per share (Title of Class of Securities) 759916109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires F |
|
| December 15, 2023 |
EX-4.1 Exhibit 4.1 Execution Version REPLIGEN CORPORATION AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of December 14, 2023 1.00% Convertible Senior Notes due 2028 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 14 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Desi |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission |
|
| December 7, 2023 |
EX-99.2 Exhibit 99.2 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN ANNOUNCES PRIVATE CONVERTIBLE TRANSACTION OF $600 MILLION PRINCIPAL AMOUNT OF 1.00% CONVERTIBLE SENIOR NOTES DUE 2028 THROUGH EXCHANGE AND NEW SUBSCRIPTION AGREEMENTS WALTHAM, Mass., December 7, 2023 — Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, i |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission F |
|
| December 7, 2023 |
EX-99.1 Exhibit 99.1 Execution Version December 6, 2023 Repligen Corporation 41 Seyon Street, Bldg. 1, Suite 100 Waltham, MA 02453 Attention: Chief Financial Officer Re: Exchange and/or Subscription for Repligen Corporation Convertible Senior Notes due 2028 Ladies and Gentlemen: Repligen Corporation, a Delaware corporation, (the “Company”), is offering a new series of its Convertible Senior Notes |
|
| October 31, 2023 |
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance • Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 million • Orders strengthened with total book-to-bill ratio of 1.07 • Narrows full year revenue guidan |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission F |
|
| October 31, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made as of September 8, 2023 between Repligen Corporation, a Delaware corporation (the “Company”), and Olivier Loeillot (the “Executive”) and shall become effective on the first date of the Executive’s employment with the Company, which date is currently anticipated to be October 1, 2023 (such date, or another date if |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORAT |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 2, 2023 |
REPLIGEN APPOINTS OLIVIER LOEILLOT AS PRESIDENT AND CHIEF COMMERCIAL OFFICER Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN APPOINTS OLIVIER LOEILLOT AS PRESIDENT AND CHIEF COMMERCIAL OFFICER WALTHAM, Mass., October 2, 2023 — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillo |
|
| September 26, 2023 |
September 26, 2023 Repligen to Acquire Metenova AB Exhibit 99.2 Safe Harbor / Non-GAAP Financial Measures This press release contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regardi |
|
| September 26, 2023 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 26, 2023 |
REPLIGEN ANNOUNCES AGREEMENT TO ACQUIRE FLUID MANAGEMENT INNOVATOR METENOVA Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN ANNOUNCES AGREEMENT TO ACQUIRE FLUID MANAGEMENT INNOVATOR METENOVA • Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applications • Expands Repligen’s Fluid Management portfolio, complements single-use bag offering WALTHAM, Mass., |
|
| September 12, 2023 |
REPLIGEN APPOINTS JASON K. GARLAND AS CHIEF FINANCIAL OFFICER Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN APPOINTS JASON K. GARLAND AS CHIEF FINANCIAL OFFICER WALTHAM, Mass., September 12, 2023 — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed Jason K. Garland as Chief Financial Officer (“CFO”), |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 12, 2023 |
EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made as of September 8, 2023 between Repligen Corporation, a Delaware corporation (the “Company”), and Jason Garland (the “Executive”) and shall become effective on the first date of the Executive’s employment with the Company, which date is currently anticipated to be September 25, 2023 (such date, or another |
|
| August 2, 2023 |
Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance • Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year • Adjusts full year revenue guidance to range of $635-$ |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION ( |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 22, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF REPLIGEN CORPORATION Pursuant to Section 242 of the General Corporation Law of the State of Delaware Repligen Corporation, a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: 1. The Certificate of Incorporation of the Corpora |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 2, 2023 |
Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance • Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currency • Reports first quarter gross margin of 55.2% on both GAAP and adju |
|
| May 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 12, 2023 |
EX-99.1 Exhibit 99.1 Repligen to Acquire FlexBiosys Inc. April 12, 2023 1 Safe Harbor / Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements in this presentation which are not strictly historical statements including, without limitation, express or implied statements or guidance regarding Repligen’s estimate |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 11, 2023 |
PROXY STATEMENT 2023 ANNUAL MEETING OF SHAREHOLDERSNoticeof2023AnnualMeetingofShareholdersandProxyStatement ANNUALMEETING ITEMSOFBUSINESS DATE: Thursday May18,2023 1. |
|
| March 24, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other t han the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exac |
|
| February 22, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Subsidiary Name Subsidiary Jurisdiction Repligen Sweden AB Sweden Repligen GmbH Germany Repligen Singapore Pte. Ltd. Singapore Repligen Europe B.V. Netherlands Repligen (Shanghai) Biotechnology Co. Ltd. China Repligen Japan LLC Japan Repligen India Private Limited India Repligen Korea Co., Ltd. South Korea ARTeSYN Biosolutions Holdings Ireland Ltd. Irela |
|
| February 22, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission |
|
| February 22, 2023 |
Repligen Reports Fourth Quarter and Full Year 2022 Financial Results EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2022 Financial Results — Fourth quarter revenue of $186.8 million represents year-over-year organic growth of 4% and 5% growth at constant currency — Full year revenue of $801.5 million represents year-over-year organic growth of 22% and 25% gr |
|
| February 15, 2023 |
RGEN / Repligen Corporation / EDDLEMAN ROY T - AMENDMENT NO. 5 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea173414-13ga5royreplien.htm AMENDMENT NO. 5 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 5)* Under the Securities Exchange Act of 1934 Repligen Corporation (Name of Issuer) Common Stock, $.01 par value per share (Title of Class of Securities) 759916109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires F |
|
| February 9, 2023 |
RGEN / Repligen Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01785-repligencorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Repligen Corp. Title of Class of Securities: Common Stock CUSIP Number: 759916109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the ru |
|
| February 9, 2023 |
Repligen Appoints Martin D. Madaus to Board of Directors Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Appoints Martin D. Madaus to Board of Directors WALTHAM, MA – February 9, 2023 – Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus. Dr. Madaus brings to the Repligen board over 25 years of i |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 1, 2022 |
Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance - Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic - Delivers base business growth of 29% for the qu |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORAT |
|
| November 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission F |
|
| August 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 2, 2022 |
Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance ? Record revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year) ? Strong organic revenue growth of 29% and strong bas |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION ( |
|
| June 1, 2022 |
Exhibit 10.2 THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Third Amended and Restated Employment Agreement (the ?Agreement?) is made this 26th day of May 2022 between Repligen Corporation, a Delaware corporation (the ?Company?), and Anthony Hunt (the ?Executive?) and shall become effective on May 26, 2022 (the ?Effective Date?). WHEREAS, the Company and the Executive are parties to the Seco |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 1, 2022 |
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors WALTHAM, MA ? May 26, 2022 ? Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert. Dr. Konstantinov bring |
|
| June 1, 2022 |
Exhibit 10.1 REPLIGEN CORPORATION AMENDED AND RESTATED SEVERANCE AND CHANGE IN CONTROL PLAN Repligen Corporation (the ?Company?) considers it essential to the best interests of its stockholders to foster the continuous employment of key management personnel. The Board of Directors of the Company (the ?Board?) recognizes, however, that, as is the case with many publicly held corporations, the possi |
|
| June 1, 2022 |
Repligen Corporation Amended and Restated Non-Employee Directors' Compensation Policy. Exhibit 10.3 REPLIGEN CORPORATION AMENDED AND RESTATED NON-EMPLOYEE DIRECTORS? COMPENSATION POLICY Cash Fees Annual Retainer: Annual Retainer Board of Directors (the ?Board?) Each Non-Employee Member of the Board $ 60,000 Additional Retainer for the Chairperson $ 95,000 Audit Committee Committee Chairperson $ 30,000 Other Committee Members $ 10,000 Compensation Committee Committee Chairperson $ 20 |
|
| April 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2022 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION |
|
| April 27, 2022 |
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance ? Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency ? Organic revenue growth of 44% for the quarter and base business growth |
|
| April 11, 2022 |
DEF 14A 1 d270359ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commi |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definit |
|
| April 11, 2022 | ||
| March 8, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2022 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission File |
|
| March 8, 2022 |
Exhibit 4.1 Execution Version REPLIGEN CORPORATION AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee SECOND SUPPLEMENTAL INDENTURE Dated as of March 4, 2022 to Indenture for Senior Debt Securities Dated as of July 19, 2019 0.375% Convertible Senior Notes due 2024 SECOND SUPPLEMENTAL INDENTURE dated as of March 4, 2022 (this ?Second Supplemental Indenture?), between REPLIGEN CORPORATION, a Del |
|
| February 17, 2022 |
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2021 Financial Results ? Record revenue of $186.5 million for the quarter, and year-over-year growth of 72% ? Record revenue of $670.5 million for the year, and year-over-year growth of 83% ? Organic revenue growth of 69% for the fourth quarter and 71% |
|
| February 17, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Subsidiary Name Subsidiary Jurisdiction Repligen Sweden AB Sweden Repligen GmbH Germany Repligen Singapore Pte. Ltd. Singapore Repligen Europe B.V. Netherlands Repligen (Shanghai) Biotechnology Co. Ltd. China Repligen Japan LLC Japan Repligen India Private Limited India Repligen Korea Co., Ltd. South Korea ARTeSYN Biosolutions Holdings Ireland Limited Ir |
|
| February 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exac |
|
| February 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission |
|
| February 10, 2022 |
RGEN / Repligen Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Repligen Corp. Title of Class of Securities: Common Stock CUSIP Number: 759916109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 3, 2022 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 16, 2021 |
Exhibit 99.1 Repligen Acquistion of BioFlex Solutions* December 16, 2021 *Acquisition of BioFlex Solutions, LLC includes the company?s manufacturing arm, Newton T&M Safe Harbor This presentation contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this presentation which are not strictly historical statements including, w |
|
| December 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2021 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 5, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-231098 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(1)(2) Amount of Registration Fee Common Stock, par value $0.01 per share 271,096 $283.76 $76,926,201.00 $7,131.06 (1) Repre |
|
| October 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission F |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORAT |
|
| October 28, 2021 |
Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance ? Reports record revenue of $178.2 million for the quarter, representing year-over-year growth of 89% and organic growth of 77% ? Raises revenue guidance to $655-$665 million for full year 2021 ? Co |
|
| September 16, 2021 |
Repligen Announces Agreement to Acquire Avitide Inc. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Announces Agreement to Acquire Avitide Inc. ? Proposed acquisition strengthens Repligen?s Proteins business ? Adds a market leader in affinity ligand discovery and development and complements established partnership with Navigo GmbH ? Strategically moves Repligen into affinity resin solut |
|
| September 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2021 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 16, 2021 |
Repligen Announces Agreement to Acquire Avitide, Inc. Tony J. Hunt, President and CEO September 16, 2021 Jon K. Snodgres, CFO Exhibit 99.2 Safe Harbor This presentation contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this presentation which are not strictly historical statements including, without limitation, express |
|
| September 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2021 Repligen Corporation (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPL |
|
| July 27, 2021 |
EXHIBIT 10.1 REPLIGEN CORPORATION 2018 STOCK OPTION AND INCENTIVE PLAN SUB-PLAN FOR FRENCH-QUALIFIED RESTRICTED STOCK UNITS This appendix (the ?Sub-Plan for French-Qualified Restricted Stock Units?) amends and supplements certain terms and conditions of the Repligen Corporation 2018 Stock Option and Incentive Plan (the ?Plan?), in accordance with Section 2(g) of the Plan. All capitalized terms use |
|
| July 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2021 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission File |
|
| July 27, 2021 |
Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance ? Reported revenue was $163.0 million for the quarter, representing year-over-year growth of 86% and organic growth of 69% ? Revenue guidance raised to $625-$645 million for full year 2021 ? Acquis |
|
| May 19, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Repligen Corporation (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 5, 2021 |
definitive proxy statement on Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| May 5, 2021 |
PROXY STATEMENT for 2021 ANNUAL MEETING OF SHAREHOLDERSNotice of Annual Meeting of Shareholders and Proxy Statement ANNUAL MEETING ITEMS OF BUSINESS 13 Date Thursday May 13, 2021 Time 12:00 p. |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REP |
|
| May 4, 2021 |
Repligen Corporation Amended and Restated Non-Employee Directors’ Compensation Policy. Exhibit 10.1 REPLIGEN CORPORATION AMENDED AND RESTATED NON-EMPLOYEE DIRECTORS? COMPENSATION POLICY Cash Fees Annual Retainer: Annual Retainer Board of Directors (the ?Board?) Each Non-Employee Member of the Board $ 55,000 Additional Retainer for the Chairperson $ 95,000 Audit Committee Committee Chairperson $ 30,000 Other Committee Members $ 10,000 Compensation Committee Committee Chairperson $ 20 |
|
| May 4, 2021 |
Repligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance - Reported revenue was $142.8 million for the quarter, representing year-over-year growth of 88% and organic growth of 69% - Growth driven by combination of COVID-related demand, base business stren |
|
| April 21, 2021 |
PROXY STATEMENT for 2021 ANNUAL MEETING OF SHAREHOLDERSNotice of Annual Meeting of Shareholders and Proxy Statement ANNUAL MEETING ITEMS OF BUSINESS 13 Date Thursday May 13, 2021 Time 12:00 p. |
|
| April 21, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| February 24, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission |
|
| February 24, 2021 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Subsidiary Name Subsidiary Jurisdiction Repligen Sweden AB Sweden Repligen GmbH Germany Repligen Singapore Pte. Ltd. Singapore Repligen Europe B.V. Netherlands Repligen (Shanghai) Biotechnology Co. Ltd. China Repligen Japan LLC Japan Repligen India Private Limited India Repligen Korea Co. Ltd. South Korea ARTeSYN Biosolutions Holdings Ireland Limited Ire |
|
| February 24, 2021 |
Repligen Reports Fourth Quarter and Full Year 2020 Financial Results EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2020 Financial Results • Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growth • Organic revenue growth was 47% for the fourth quarter and |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Repligen Corp. Title of Class of Securities: Common Stock CUSIP Number: 759916109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 4)* Under the Securities Exchange Act of 1934 Repligen Corporation (Name of Issuer) Common Stock, $.01 par value per share (Title of Class of Securities) 759916109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 28, 2021 |
EX-3.1 Exhibit 3.1 THIRD AMENDED AND RESTATED BY-LAWS OF REPLIGEN CORPORATION ARTICLE I STOCKHOLDERS SECTION 1. Place of Meetings. All meetings of stockholders shall be held at such place within or without the State of Delaware as may be designated from time to time by the Board of Directors or, if not so designated, at the principal office of Repligen Corporation (the “Corporation”). SECTION 2. A |
|
| January 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2021 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 8, 2020 |
EX-99.1 Exhibit 99.1 Source: Repligen Corporation December 7, 2020 07:22 ET Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock WALTHAM, Mass., December 7, 2020 (GLOBE NEWSWIRE) – Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of 1.5 million shares of its common stock. In addition, Repligen Corporation expects |
|
| December 8, 2020 |
EX-99.2 Exhibit 99.2 Source: Repligen Corporation December 7, 2020 21:41 ET Repligen Corporation Prices Public Offering of Shares of Common Stock WALTHAM, Mass., December 7, 2020 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a public offering price of $181 per share. In addition, Re |
|
| December 8, 2020 |
EX-1.1 2 d217539dex11.htm EX-1.1 Exhibit 1.1 1,500,000 Shares Repligen Corporation UNDERWRITING AGREEMENT December 7, 2020 J.P. MORGAN SECURITIES LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Stifel, Nicolaus & Company, Incorporated 787 7th Avenue, 11th Floor New York, New Y |
|
| December 8, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 8, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-231098 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0.01 per share 1,725,000 $181.00 $312,225,000.00 $34,063.75 (1) Inc |
|
| December 7, 2020 |
SUBJECT TO COMPLETION, DATED DECEMBER 7, 2020 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission F |
|
| November 5, 2020 |
Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance – Reports record quarterly revenue of $94.1 million with strong margin expansion – Overall revenue grew 35% year-over-year, with organic growth of 31% – Raises revenue guidance to $348-$352 |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 |
|
| October 27, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 27, 2020 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 27, 2020 |
EX-99.2 Repligen Announces Agreement to Acquire ARTeSYN Biosolutions Tony J. Hunt, President and CEO October 27th, 2020 Jon K. Snodgres, CFO Exhibit 99.2 Safe Harbor This presentation contains forward looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| October 27, 2020 |
EX-99.1 2 d66585dex991.htm EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions • Proposed ARTeSYN acquisition adds gold standard single-use downstream bioprocessing systems • Advances Repl |
|
| July 30, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPL |
|
| July 30, 2020 |
Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance EX-99.1 2 d912522dex991.htm EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance • Reports record quarterly revenue of $87.5 million • Overall revenue grew 24% year-over-year, with organic growth of 19% • Raises revenue guidance to $332-$340 |
|
| July 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2020 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission File |
|
| July 10, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2020 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 10, 2020 |
EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO LEASE This First Amendment to Lease (the “Amendment”) is made and entered into this 7th day of July, 2020 (the “Effective Date”), by and between U.S. REIF 111 LOCKE DRIVE MASSACHUSETTS, LLC, a Delaware limited liability company (the “Landlord”) and REPLIGEN CORPORATION, a Delaware corporation (the “Tenant”). RECITALS WHEREAS, Landlord and Tenant entered into |
|
| June 29, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 29, 2020 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 29, 2020 |
EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Announces Agreement to Acquire Engineered Molding Technology Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing WALTHAM, MA – June 29, 2020 – Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today a |
|
| June 15, 2020 |
Repligen Appoints Carrie Eglinton Manner to Board of Directors EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Appoints Carrie Eglinton Manner to Board of Directors WALTHAM, MA – June 15, 2020 – Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors. Ms. Eglinton Manner brings to the director role |
|
| June 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 15, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2020 Repligen Corporation (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 6, 2020 |
Repligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance – Reports record quarterly revenue of $76.1 million – Overall revenue grew 25% year-over-year, with organic growth of 16% – Strong order load through first four months WALTHAM, Mass. – May 6 |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REP |
|
| May 6, 2020 |
Repligen Corporation Amended and Restated Non-Employee Directors’ Compensation Policy. EX-10.1 EXHIBIT 10.1 REPLIGEN CORPORATION AMENDED AND RESTATED NON-EMPLOYEE DIRECTORS’ COMPENSATION POLICY Cash Fees Annual Retainer: Annual Retainer Board of Directors (the “Board”) Each Non-Employee Member of the Board $ 55,000 Additional Retainer for the Chairperson $ 95,000 Audit Committee Committee Chairperson $ 30,000 Other Committee Members $ 10,000 Compensation Committee Committee Chairper |
|
| April 28, 2020 |
begin 644 d868307ddef14a1.pdf M)5!$1BTQ+C8-)>+CS],-"C$@,"!O8FH*/#PO365T861A=&$@,B P(%(O4&%G M97,@,R P(%(O5'EP92]#871A;&]G/CX*96YD;V)J"C(@,"!O8FH*/#PO3&5N M9W1H(#,S-S@O4W5B='EP92]834PO5'EP92]-971A9&%T83X^G)E4WI.5&-Z M:V,Y9"(/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X M.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C8M8S Q-2 X,2XQ-3DX,#DL(#(P M,38O,3$O,3$M,#$Z-#(Z,38@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS |
|
| April 28, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 27, 2020 |
Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors WALTHAM, MA – February 27, 2020 – Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of Directors. Dr. Mhatre brings to the director role over 25 years |
|
| February 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 26, 2020 |
Subsidiaries of the Registrant. EX-21.1 Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Subsidiary Name Subsidiary Jurisdiction Repligen Sweden AB Sweden Repligen GmbH Germany Repligen Singapore Pte. Ltd. Singapore Repligen Europe B.V. Netherlands Repligen (Shanghai) Biotechnology Co. Ltd. China Repligen Japan LLC Japan Repligen India Private Limited India Repligen Korea Co. Ltd. South Korea Spectrum Lifesciences, LLC United States |
|
| February 26, 2020 |
EX-4.5 2 d862842dex45.htm EX-4.5 Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Repligen Corporation (the “Company,” “we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. Description of Common Stock |
|
| February 26, 2020 |
Exhibit 10.4 LEASE BETWEEN REPLIGEN CORPORATION, AS TENANT AND WEST SEYON LLC, AS LANDLORD 35 SEYON STREET, WALTHAM, MASSACHUSETTS The submission of an unsigned copy of this document to Tenant for Tenant’s consideration does not constitute an offer to lease the Premises or an option to or for the Premises. This document shall become effective and binding only upon the execution and delivery of thi |
|
| February 26, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN |
|
| February 20, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission |
|
| February 20, 2020 |
Repligen Reports Fourth Quarter and Full Year 2019 Financial Results EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2019 Financial Results • Reports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year growth • Overall organic revenue growth was 21% for the fourth quart |
|
| February 12, 2020 |
RGEN / Repligen Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Repligen Corp Title of Class of Securities: Common Stock CUSIP Number: 759916109 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| January 31, 2020 |
RGEN / Repligen Corp. / Eddleman Roy T - AMENDMENT NO. 3 SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3)* Under the Securities Exchange Act of 1934 Repligen Corporation (Name of Issuer) Common Stock, $.01 par value per share (Title of Class of Securities) 759916109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| October 31, 2019 |
Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance • Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-year • Raises revenue guidance to $267-$270 million for full year 2019, repres |
|
| October 31, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission F |
|
| October 31, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 |
|
| August 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commission |
|
| August 1, 2019 |
Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance • Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growth • Raises revenue guidance to $264-$268 million for full year 2019, represe |
|
| August 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION ( |
|
| July 22, 2019 |
EX-4.2 Exhibit 4.2 REPLIGEN CORPORATION AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of July 19, 2019 to Indenture for Senior Debt Securities Dated as of July 19, 2019 0.375% Convertible Senior Notes due 2024 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01 . Definitions 2 Section 1.02 . References to Interest 12 ARTICLE 2 ISSUE, DESCRIPTION |
|
| July 22, 2019 |
EX-4.1 Exhibit 4.1 REPLIGEN CORPORATION, Issuer AND WILMINGTON TRUST, NATIONAL ASSOCIATION, Trustee INDENTURE Dated as of July 19, 2019 Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of |
|
| July 22, 2019 |
EX-99.1 Exhibit 99.1 Source: Repligen Corporation July 19, 2019 19:42 ET Repligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters’ Options WALTHAM, Mass., July 19, 2019 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the clo |
|
| July 22, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 18, 2019 |
EX-1.1 2 d779469dex11.htm EX-1.1 Exhibit 1.1 Execution Version 1,380,000 Shares Repligen Corporation UNDERWRITING AGREEMENT July 16, 2019 J.P. MORGAN SECURITIES LLC STEPHENS INC. JANNEY MONTGOMERY SCOTT LLC As Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Stephens Inc. 111 Center Street Little Rock, Arkansas 72201 c/o Jan |
|
| July 18, 2019 |
EX-99.2 Exhibit 99.2 Source: Repligen Corporation July 17, 2019 00:14 ET Repligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024 WALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the pricing of concurrent underwritten public offerings of 1, |
|
| July 18, 2019 |
EX-99.1 6 d779469dex991.htm EX-99.1 Exhibit 99.1 Source: Repligen Corporation July 15, 2019 16:02 ET Repligen Corporation Announces Proposed Public Offerings of $100 million of Common Stock and $250 million of Convertible Senior Notes WALTHAM, Mass., July 15, 2019 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced that it has commenced concurrent underwritten publi |
|
| July 18, 2019 |
EX-1.2 Exhibit 1.2 Execution Version 0.375% Convertible Senior Notes due 2024 Repligen Corporation UNDERWRITING AGREEMENT July 16, 2019 J.P. MORGAN SECURITIES LLC As Representative of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Repligen Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to th |
|
| July 18, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 17, 2019 |
424B5 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) 0. |
|
| July 17, 2019 |
424B5 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0. |
|
| July 17, 2019 |
FWP Free Writing Prospectus Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplements each dated July 15, 2019 to the Prospectus dated April 29, 2019 Registration No. |
|
| July 15, 2019 |
SUBJECT TO COMPLETION, DATED JULY 15, 2019 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-231098 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the shares has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell |
|
| July 15, 2019 |
SUBJECT TO COMPLETION, DATED JULY 15, 2019 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-231098 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the shares has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell |
|
| July 15, 2019 |
Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 0-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| July 15, 2019 |
EX-99.5 Exhibit 99.5 C TECHNOLOGIES, INC. FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2019 AND 2018 AND INDEPENDENT ACCOUNTANTS’ REVIEW REPORT C TECHNOLOGIES, INC. TABLE OF CONTENTS Page Independent Accountants’ Review Report 1 Financial Statements Balance Sheets 2 Statements of Income 3 Statements of Stockholder’s Equity 4 Statements of Cash Flows 5 Notes to Financial Statements 6 INDEPENDE |
|
| July 15, 2019 |
EX-99.6 Exhibit 99.6 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION INDEX TO FINANCIAL STATEMENTS UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS: Introduction 2 Pro Forma Condensed Combined Consolidated Balance Sheet as of March 31, 2019 (Unaudited) 3 Pro Forma Condensed Combined Consolidated Statements of Operations for the Year Ended December 31, 2018 (Unaudited) 4 Pro |
|
| July 15, 2019 |
Financial Statements and Exhibits, Other Events 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 0-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 19, 2019 |
EX-10.2 Exhibit 10.2 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Second Amended and Restated Employment Agreement (the “Agreement”) is made this 15th day of June, 2019 between Repligen Corporation, a Delaware corporation (the “Company”), and Anthony Hunt (the “Executive”) and shall become effective on June 15, 2019 (the “Effective Date”). WHEREAS, the Company and the Executive are partie |
|
| June 19, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 19, 2019 |
EX-10.1 Exhibit 10.1 REPLIGEN CORPORATION NAMED EXECUTIVE OFFICER SEVERANCE AND CHANGE IN CONTROL PLAN Repligen Corporation (the “Company”) considers it essential to the best interests of its stockholders to foster the continuous employment of key management personnel. The Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many publicly held corporations |
|
| May 31, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 31, 2019 |
EX-10.1 2 d754343dex101.htm EX-10.1 Exhibit 10.1 FIFTH AMENDMENT THIS FIFTH AMENDMENT (the “Amendment”) is made and entered into as of May 29, 2019 (the “Effective Date”), by and between HRE-S CENTERPOINT, LLC, a Delaware limited liability company (“Landlord”) and REPLIGEN CORPORATION, a Delaware corporation (“Tenant”). RECITALS A. West Seyon LLC (as a predecessor-in-interest to Landlord) and Tena |
|
| May 21, 2019 |
Submission of Matters to a Vote of Security Holders 8-K 1 d749826d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2019 Repligen Corporation (Exact name of registrant as specified in its charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorpo |
|
| May 9, 2019 |
Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance EX-99.1 2 d746367dex991.htm EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance • Reports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growth • Raises revenue guidance to $235-$241 million for |
|
| May 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction of incorporation) (Commissi |
|
| May 9, 2019 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 1, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d749656d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 000-14656 04-2729386 (State or Other Jurisdiction of Incorpora |
|
| May 1, 2019 |
Repligen Corporation Prices Public Offering of Shares of Common Stock EX-99.2 5 d749656dex992.htm EX-99.2 Exhibit 99.2 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Corporation Prices Public Offering of Shares of Common Stock WALTHAM, Mass., April 30, 2019 — Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 2,734,375 shares of its common stock at a public offering |
|
| May 1, 2019 |
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock EX-99.1 4 d749656dex991.htm EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock WALTHAM, Mass., April 29, 2019 — Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of $175,000,000 in shares of its common s |
|
| May 1, 2019 |
EX-1.1 Exhibit 1.1 Execution Version 2,734,375 Shares Repligen Corporation UNDERWRITING AGREEMENT April 30, 2019 J.P. MORGAN SECURITIES LLC STEPHENS INC. As Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Stephens Inc. 111 Center Street Little Rock, Arkansas 72201 Ladies and Gentlemen: Repligen Corporation, a Delaware corpo |
|
| May 1, 2019 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-231098 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0.01 per share 3,144,531 $64.00 $201,249,984.00 $24,391.50(1) (1) I |
|
| April 29, 2019 |
SUBJECT TO COMPLETION, DATED APRIL 29, 2019 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| April 29, 2019 |
RPGN / REPLIGEN CORP S-3ASR S-3ASR S-3ASR Table of Contents As filed with the Securities and Exchange Commission on April 29, 2019. |
|
| April 29, 2019 |
Form of Subordinated Indenture (including Form of Subordinated Note). EX-4.4 3 d668819dex44.htm EX-4.4 Exhibit 4.4 REPLIGEN CORPORATION, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 201[●] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of |
|
| April 29, 2019 |
Form of Senior Indenture (including Form of Senior Note). EX-4.3 Exhibit 4.3 REPLIGEN CORPORATION, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 201[●] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certif |
|
| April 29, 2019 |
EX-99.2 3 d600172dex992.htm EX-99.2 Exhibit 99.2 C TECHNOLOGIES, INC. FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2018 AND 2017 AND INDEPENDENT AUDITORS’ REPORT C TECHNOLOGIES, INC. TABLE OF CONTENTS Page Independent Auditors’ Report 1 Financial Statements Balance Sheets 2 Statements of Income 3 Statements of Stockholder’s Equity 4 Statements of Cash Flows 5 Notes to Financial Statements 6 INDEP |
|
| April 29, 2019 |
EX-99.4 Exhibit 99.4 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION OF C TECHNOLOGIES, INC. The information contained in this section is based on C Technologies’ historical financial condition and results of operations and does not give effect to the Acquisition. The Acquisition will have a material impact on the results of operations of the C Technologies bus |
|
| April 29, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K / A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 0-14656 04-2729386 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 29, 2019 |
EX-99.3 Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION INDEX TO FINANCIAL STATEMENTS UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS: Introduction 2 Pro Forma Condensed Combined Consolidated Balance Sheet as of December 31, 2018 (Unaudited) 3 Pro Forma Condensed Combined Consolidated Statements of Income for the Year Ended December 31, 2018 (Unaudited) 4 Notes to Pro |
|
| April 26, 2019 |
EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results • Proposed acquisition establishes a key franchise for Repligen in the rapidly growing Process Analytics segment of bioprocessing • Ad |
|
| April 26, 2019 |
EX-2.1 2 d737524dex21.htm EX-2.1 Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE REPLIGEN CORPORATION HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO REPLIGEN CORPORATION IF PUBLICLY DISCLOSED. EXECUTION VERSION STOCK PURCHASE AGREEMENT BY AND AMONG REPLIGEN CORPORATION, C TECHNOLO |
|
| April 26, 2019 |
8-K 1 d737524d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in charter) Delaware 0-14656 04-2729386 (State or Other Jurisdiction of Incorporati |
|
| April 18, 2019 |
DEF 14A 1 d686074ddef14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the |
|
| March 1, 2019 |
EX-10.17 EXHIBIT 10.17 September 1, 2016 Ralf Kuriyel 111 Willard Road Brookline, MA 02445 Dear Ralf: Repligen Corporation (“Repligen” or the “Company”) is pleased to offer you the full-time position of Senior Vice President, Research & Development reporting to Tony Hunt, CEO. We are excited about the prospect of you joining our team, and look forward to the addition of your professionalism and ex |
|
| March 1, 2019 |
Subsidiaries of the Registrant. EX-21.1 Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Subsidiary Name Subsidiary Jurisdiction Repligen Sweden AB Sweden Repligen GmbH Germany Repligen Singapore Pte. Ltd. Singapore Repligen Europe B.V. Netherlands Repligen (Shanghai) Biotechnology Co. Ltd. China Repligen Japan LLC Japan Repligen India Private Limited India Repligen Korea Co. Ltd. South Korea Spectrum Lifesciences, LLC United States |
|
| March 1, 2019 |
EX-10.4 Exhibit 10.4 LEASE BETWEEN REPLIGEN CORPORATION, AS TENANT AND WEST SEYON LLC, AS LANDLORD 35 SEYON STREET, WALTHAM, MASSACHUSETTS The submission of an unsigned copy of this document to Tenant for Tenant’s consideration does not constitute an offer to lease the Premises or an option to or for the Premises. This document shall become effective and binding only upon the execution and deliver |
|
| March 1, 2019 |
10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 21, 2019 |
Repligen Reports Fourth Quarter and Full Year 2018 Financial Results Exhibit 99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2018 Financial Results • Record quarterly revenue of $51.9 million represents 25% year-over-year growth, and record annual revenue of $194.0 million represents 37% year-over-year growth • Overall organic revenue growth was 25% for the four |
|
| February 21, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d711749d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2019 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-14656 04-2729386 (State or other jurisdiction |
|
| February 14, 2019 |
RGEN / Repligen Corp. / TimesSquare Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 Repligen Corporation (Name of Issuer) Common Stock, Class A, $.01 par value (Title of Class of Securities) 759916109 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 11, 2019 |
RGEN / Repligen Corp. / VANGUARD GROUP INC Passive Investment repligencorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Repligen Corp Title of Class of Securities: Common Stock CUSIP Number: 759916109 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to design |
|
| January 31, 2019 |
RGEN / Repligen Corp. / Eddleman Roy T - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) Under the Securities Exchange Act of 1934 Repligen Corporation (Name of Issuer) Common Stock, $.01 par value per share (Title of Class of Securities) 759916109 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
